YAP/TAZ axis was involved in the effects of metformin on breast cancer
Breast cancer is malignant tumours in women. A large amount of data analysis shows that Metformin has been shown to play a significance role in reducing the risk of breast cancer, but the mechanism remains unclear. The hippo signalling pathway can be involved in the formation, metastasis and recurrence of breast cancer. When YAP/TAZ is activated, cells can overcome contact inhibition and enter a state of uncontrolled proliferation. Therefore, YAP/TAZ is considered a potential therapeutic target for breast cancer. Eighty breast cancer patients, forty cases of triple-negative and forty cases of HER-2+, were included in this study. In vitro and in vivo experiments were used to confirm the YAP/TAZ axis was involved in the effects of metformin on breast cancer. EMT plays an important role in breast cancer, including chemoresistance and tumour metastasis. Our results confirmed that YAP could modulate the activity of EMT, which in turn altered tumour resistance. Therefore, MET can inhibit EMT by reducing the expression of YAP, and finally achieve the therapeutic effect of breast cancer. Our findings support metformin as a novel YAP inhibitor and potentially as a novel breast cancer drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of chemotherapy (Florence, Italy) - 35(2023), 7 vom: 21. Nov., Seite 627-637 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1120009X.2022.2162221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351669256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351669256 | ||
| 003 | DE-627 | ||
| 005 | 20231226051935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1120009X.2022.2162221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351669256 | ||
| 035 | |a (NLM)36656142 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a YAP/TAZ axis was involved in the effects of metformin on breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Breast cancer is malignant tumours in women. A large amount of data analysis shows that Metformin has been shown to play a significance role in reducing the risk of breast cancer, but the mechanism remains unclear. The hippo signalling pathway can be involved in the formation, metastasis and recurrence of breast cancer. When YAP/TAZ is activated, cells can overcome contact inhibition and enter a state of uncontrolled proliferation. Therefore, YAP/TAZ is considered a potential therapeutic target for breast cancer. Eighty breast cancer patients, forty cases of triple-negative and forty cases of HER-2+, were included in this study. In vitro and in vivo experiments were used to confirm the YAP/TAZ axis was involved in the effects of metformin on breast cancer. EMT plays an important role in breast cancer, including chemoresistance and tumour metastasis. Our results confirmed that YAP could modulate the activity of EMT, which in turn altered tumour resistance. Therefore, MET can inhibit EMT by reducing the expression of YAP, and finally achieve the therapeutic effect of breast cancer. Our findings support metformin as a novel YAP inhibitor and potentially as a novel breast cancer drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a YAP/TAZ activity | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a epithelial–mesenchymal transition | |
| 650 | 4 | |a hippo signalling pathway | |
| 650 | 4 | |a novel drug | |
| 650 | 4 | |a nuclear translocation | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a YAP-Signaling Proteins |2 NLM | |
| 650 | 7 | |a WWTR1 protein, human |2 NLM | |
| 650 | 7 | |a Transcriptional Coactivator with PDZ-Binding Motif Proteins |2 NLM | |
| 700 | 1 | |a Cai, Hongke |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Yuanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Longjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yongqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiayi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chemotherapy (Florence, Italy) |d 1989 |g 35(2023), 7 vom: 21. Nov., Seite 627-637 |w (DE-627)NLM012678473 |x 1973-9478 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2023 |g number:7 |g day:21 |g month:11 |g pages:627-637 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1120009X.2022.2162221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2023 |e 7 |b 21 |c 11 |h 627-637 | ||